# 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct00943449/  
OnCo record `nct00943449` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Resminostat and Sorafenib in Hepatocellular carcinoma, run by 4SC AG, completed.

## Summary

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT00943449 by 4SC AG, with 57 participants recorded, started 2009-07 and reaching its primary completion in 2012-06. Interventions recorded: 4SC-201, Sorafenib. Conditions recorded: Hepatocellular Carcinoma.

Linked to the drug Resminostat because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00943449
- Phase: 2
- Setting: A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment
- Sponsor: 4SC AG
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT00943449: https://clinicaltrials.gov/study/NCT00943449

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Resminostat](https://onco.cc/drugs/resminostat/), [Sorafenib](https://onco.cc/drugs/sorafenib/)
- companies: [4SC](https://onco.cc/companies/4sc/)

---
JSON: https://onco.cc/api/v1/entities/nct00943449.json